In contrast, MAGEA3 exhibited a more consistent correlation with bevacizumab resistance across different samples, suggesting that MAGEA3 may have a more stable prognostic effect than VEGF in CRC patients. Here, MAGEA3 is linked to colorectal carcinoma.